Barinthus Biotherapeutics (BRNS) Convertible Debt (2020)
Barinthus Biotherapeutics (BRNS) reported Convertible Debt of $44.7 million for Q4 2020.
Barinthus Biotherapeutics (BRNS) Convertible Debt (2020) Analysis & Trends
Barinthus Biotherapeutics has reported Convertible Debt for 1 years, with the latest figure at $44.7 million in Q4 2020.
- For the quarter ending Q4 2020, Convertible Debt changed N/A year-over-year to $44.7 million; the trailing twelve-month figure through Dec 2020 stood at $44.7 million (changed N/A YoY), and the FY2020 full-year result was $44.7 million, changed N/A from the prior year.
- Convertible Debt for Q4 2020 stood at $44.7 million.
- The five-year high for Convertible Debt was $44.7 million in Q4 2020, with the low at $44.7 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - |
| 10 | Barinthus Biotherapeutics | 27.08 Mn | -40.03 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 44.70 Mn |